Pharming Group NV (PHARM) - Net Assets

Latest as of September 2025: €264.64 Million EUR ≈ $309.40 Million USD

Based on the latest financial reports, Pharming Group NV (PHARM) has net assets worth €264.64 Million EUR (≈ $309.40 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€473.79 Million ≈ $553.90 Million USD) and total liabilities (€209.14 Million ≈ $244.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Pharming Group NV's balance sheet for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€264.64 Million
% of Total Assets	55.86%
Annual Growth Rate	10.16%
5-Year Change	16.57%
10-Year Change	721.71%
Growth Volatility	118.77

Pharming Group NV - Net Assets Trend (2005–2024)

This chart illustrates how Pharming Group NV's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Pharming Group NV to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Pharming Group NV (2005–2024)

The table below shows the annual net assets of Pharming Group NV from 2005 to 2024. For live valuation and market cap data, see PHARM company net worth.

Year	Net Assets	Change
2024-12-31	€214.16 Million ≈ $250.38 Million	+8.13%
2023-12-31	€198.05 Million ≈ $231.55 Million	-3.22%
2022-12-31	€204.64 Million ≈ $239.24 Million	+6.19%
2021-12-31	€192.72 Million ≈ $225.31 Million	+4.89%
2020-12-31	€183.73 Million ≈ $214.80 Million	+56.69%
2019-12-31	€117.26 Million ≈ $137.09 Million	+66.00%
2018-12-31	€70.64 Million ≈ $82.58 Million	+213.15%
2017-12-31	€22.56 Million ≈ $26.37 Million	-21.91%
2016-12-31	€28.89 Million ≈ $33.77 Million	+10.83%
2015-12-31	€26.06 Million ≈ $30.47 Million	-28.18%
2014-12-31	€36.29 Million ≈ $42.43 Million	+424.55%
2013-12-31	€6.92 Million ≈ $8.09 Million	+168.36%
2012-12-31	€-10.12 Million ≈ $-11.83 Million	-557.23%
2011-12-31	€-1.54 Million ≈ $-1.80 Million	-111.46%
2010-12-31	€13.43 Million ≈ $15.70 Million	-29.58%
2009-12-31	€19.07 Million ≈ $22.30 Million	+9.33%
2008-12-31	€17.45 Million ≈ $20.40 Million	-65.51%
2007-12-31	€50.58 Million ≈ $59.13 Million	-23.11%
2006-12-31	€65.78 Million ≈ $76.91 Million	+93.26%
2005-12-31	€34.04 Million ≈ $39.79 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Pharming Group NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 7446610304.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	€7.77 Million	3.63%
Other Comprehensive Income	€-201.83K	-0.09%
Other Components	€471.95 Million	220.37%
Total Equity	€214.16 Million	100.00%

Pharming Group NV Competitors by Market Cap

The table below lists competitors of Pharming Group NV ranked by their market capitalization.

Company	Market Cap
Surge Energy Inc. TO:SGY	$737.11 Million
Afya Ltd NASDAQ:AFYA	$737.13 Million
GH RESEARCH PLC DL-025 F:1KA	$737.24 Million
Argo Properties NV TA:ARGO	$737.24 Million
Magic Software Enterprises Ltd TA:MGIC	$736.62 Million
Shenzhen Liande Automatic Equipment Co Ltd SHE:300545	$736.55 Million
China Shineway Pharmaceutical Group Limited F:C1S	$736.52 Million
Suzhou Etron Technologies Co Ltd SHG:603380	$736.49 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharming Group NV's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 198,054,587 to 214,163,388, a change of 16,108,801 (8.1%).
Net loss of 10,644,363 reduced equity.
Other comprehensive income increased equity by 1,660,294.
Other factors increased equity by 25,092,870.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-10.64 Million	-4.97%
Other Comprehensive Income	€1.66 Million	+0.78%
Other Changes	€25.09 Million	+11.72%
Total Change	€-	8.13%

Book Value vs Market Value Analysis

This analysis compares Pharming Group NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.91x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.21x to 2.91x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-12-31	€4.27	€0.90	x
2006-12-31	€7.58	€0.90	x
2007-12-31	€5.52	€0.90	x
2008-12-31	€1.89	€0.90	x
2009-12-31	€1.63	€0.90	x
2010-12-31	€0.54	€0.90	x
2011-12-31	€-0.03	€0.90	x
2012-12-31	€-0.14	€0.90	x
2013-12-31	€0.03	€0.90	x
2014-12-31	€0.09	€0.90	x
2015-12-31	€0.06	€0.90	x
2016-12-31	€0.07	€0.90	x
2017-12-31	€0.05	€0.90	x
2018-12-31	€0.11	€0.90	x
2019-12-31	€0.17	€0.90	x
2020-12-31	€0.27	€0.90	x
2021-12-31	€0.27	€0.90	x
2022-12-31	€0.29	€0.90	x
2023-12-31	€0.30	€0.90	x
2024-12-31	€0.31	€0.90	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharming Group NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -4.97%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -3.71%
• Asset Turnover: 0.74x
• Equity Multiplier: 1.81x
Recent ROE (-4.97%) is above the historical average (-96.04%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	-62.14%	-4409.63%	0.01x	1.20x	€-24.56 Million
2006	-37.11%	-12582.31%	0.00x	1.59x	€-30.99 Million
2007	-102.65%	-5161.16%	0.01x	3.30x	€-56.98 Million
2008	-209.09%	-3946.54%	0.01x	5.35x	€-38.22 Million
2009	-240.82%	-2925.18%	0.02x	4.20x	€-47.84 Million
2010	-518.84%	-9837.17%	0.02x	3.43x	€-76.41 Million
2011	0.00%	-570.32%	0.12x	0.00x	€-22.01 Million
2012	0.00%	-227.01%	0.63x	0.00x	€-30.85 Million
2013	-300.60%	-220.05%	0.22x	6.27x	€-21.49 Million
2014	-19.32%	-27.22%	0.38x	1.87x	€-10.64 Million
2015	-41.77%	-91.96%	0.19x	2.42x	€-13.49 Million
2016	-63.84%	-110.48%	0.13x	4.62x	€-21.33 Million
2017	-425.26%	-89.22%	0.54x	8.84x	€-98.18 Million
2018	40.47%	18.50%	0.63x	3.47x	€21.53 Million
2019	34.58%	21.41%	0.74x	2.18x	€28.82 Million
2020	20.54%	16.53%	0.54x	2.28x	€19.37 Million
2021	8.30%	8.43%	0.48x	2.06x	€-3.28 Million
2022	6.68%	6.65%	0.48x	2.08x	€-6.79 Million
2023	-4.93%	-4.30%	0.53x	2.15x	€-29.56 Million
2024	-4.97%	-3.71%	0.74x	1.81x	€-32.06 Million

Industry Comparison

This section compares Pharming Group NV's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $43,709,000
Average return on equity (ROE) among peers: -59.27%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Pharming Group NV (PHARM)	€264.64 Million	-62.14%	0.79x	$736.80 Million
Galapagos N.V. (GLPG)	$61.14 Million	-10.70%	0.33x	$1.55 Billion
Vivoryon Therapeutics NV (VVY)	$26.28 Million	-107.84%	0.17x	$37.91 Million

About Pharming Group NV

AS:PHARM Netherlands Biotechnology

Market Cap

$736.80 Million

€630.22 Million EUR

Market Cap Rank

#10212 Global

#57 in Netherlands

Share Price

€0.90

Change (1 day)

+2.47%

52-Week Range

€0.88 - €1.78

All Time High

€1.78